Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer

Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company has appointed William “Chip” Clark and David McGirr to its Board of Directors and promoted Michael Gray to Chief Operating Officer and Chief Financial Officer.

Mr. Clark is President and Chief Executive Officer of Genocea Biosciences, Inc. Mr. McGirr is former Chief Financial Officer of Cubist Pharmaceuticals, Inc. Their appointments bring additional industry expertise to Arsanis as the company advances its investigational lead product candidate, ASN100, currently in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically-ventilated patients, as well as its pipeline of novel monoclonal antibodies (mAbs) targeting serious bacterial and viral pathogens.

“We are pleased to welcome Mr. Clark and Mr. McGirr to our Board of Directors,” said René Russo, Pharm.D., BCPS, President and CEO of Arsanis. “Chip has highly relevant strategic, financial, and commercial experience with emerging biotechnology companies, particularly in the areas of immunotherapy and infectious diseases. In addition, I had the privilege of working with David previously at Cubist Pharmaceuticals and believe that his extensive financial acumen and fundraising experience will be invaluable to Arsanis. With the addition of Chip and David, along with our existing Board members and executives, we have assembled a corporate management team that complements our expert clinical advisory board to lead the company as we develop our mAb therapeutics to prevent and treat serious infections, while reducing the threat of antibiotic resistance and supporting hospital quality and antimicrobial stewardship initiatives.”

Mr. Clark has more than 20 years of biotechnology and pharmaceutical experience with a focus on commercialization, business development and venture capital financing. Prior to joining Genocea Biosciences, Inc., he served as Chief Business Officer at Vanda Pharmaceuticals Inc., a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company's strategic and business development activities, and played a central role in raising more than $220 million in multiple public and private financings. Prior to Vanda, Mr. Clark was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Additionally, he spent 10 years at SmithKline Beecham (now part of GlaxoSmithKline) in a variety of commercial roles. Mr. Clark holds a B.A. from Harvard University and an MBA from The Wharton School at the University of Pennsylvania.

Mr. McGirr has over 35 years of experience across multiple industries and private equity, most recently with Cubist Pharmaceuticals, Inc. from 2002 through 2014 where he held multiple roles including Senior Advisor to the Chief Executive Officer and Senior Vice President and Chief Financial Officer. Prior to Cubist, Mr. McGirr held senior positions at hippo Inc., GAB Robins North America, Inc., and the S.G. Warburg Group. Mr. McGirr currently serves on the boards of Insmed Incorporated (NASDAQ: INSM), Roka Bioscience, Inc. (NASDAQ: ROKA), and Rhythm Pharmaceuticals, Inc. Mr. McGirr holds a B.Sc. in civil engineering from the University of Glasgow and an MBA from The Wharton School at the University of Pennsylvania

In addition, Arsanis announced the promotion of Michael Gray, MBA, C.P.A., to the position of Chief Operating Officer and Chief Financial Officer. Mr. Gray had served as Arsanis’ Chief Financial Officer and Chief Business Officer since March 2016. “Mr. Gray’s extensive experience as a public company CFO, CBO and COO have proven invaluable in building Arsanis. In his time at the company, Mr. Gray played a central role in raising over $60 million in a private financing, established multiple strategic collaborations and simultaneously built Arsanis’ finance and business development functions,” said Dr. Russo. Prior to joining Arsanis, Mr. Gray served in various senior leadership roles from 2000 to 2016 at Curis, Inc. (NASDAQ: CRIS). Previously, Mr. Gray held positions at Reprogenesis and Ernst & Young, LLP. Mr. Gray holds a B.S. in Accounting from Bryant College and an MBA from the F.W. Olin School of Business at Babson College.

About Arsanis, Inc.

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical study for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus, or RSV.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).

For more information, please visit the Arsanis website at www.arsanis.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171004005492/en/